AML19 Pilot

• Research type

  Research Study

• Full title

  A national cancer research institute acute myeloid leukaemia working group pilot trial under the auspices of the cardiff experimental cancer medicine centre to establish the feasibility of combining the tyrosine kinase inhibitor, ponatinib with chemotherapy in patients with acute myeloid leukaemia with a flt3 mutation.

• IRAS ID

  120926

• Contact name

  REC for Wales

• Sponsor organisation

  Cardiff University, Research and Commercial Division

• Eudract number

  2013-000501-22

• ISRCTN Number

  None

• REC name

  Wales REC 3

• REC reference

  13/WA/0184

• Date of REC Opinion

  15 Jul 2013

• REC opinion

  Further Information Favourable Opinion